Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model.

ABSTRACT:

Objective

An estimated 6-10 million people in India live with active epilepsy, and less than half are treated. We analyze the health and economic benefits of three scenarios of publicly financed national epilepsy programs that provide: (1) first-line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery.

Methods

We model the prevalence and distribution of epilepsy in India using IndiaSim, an agent-based, simulation model of the Indian population. Agents in the model are disease-free or in one of three disease states: untreated with seizures, treated with seizures, and treated without seizures. Outcome measures include the proportion of the population that has epilepsy and is untreated, disability-adjusted life years (DALY

SUBMITTER: Megiddo I 

PROVIDER: S-EPMC5019268 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature